Investors Buy High Volume of Put Options on Supernus Pharmaceuticals (SUPN)

Share on StockTwits

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) saw some unusual options trading activity on Tuesday. Investors bought 2,740 put options on the company. This is an increase of approximately 3,413% compared to the average daily volume of 78 put options.

A number of research analysts have recently commented on SUPN shares. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 6th. Jefferies Financial Group lifted their price objective on shares of Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. Cantor Fitzgerald set a $56.00 price objective on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 8th. Mizuho initiated coverage on shares of Supernus Pharmaceuticals in a research note on Monday, September 17th. They set a “buy” rating and a $61.00 target price for the company. Finally, ValuEngine upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $55.30.

NASDAQ SUPN opened at $47.41 on Wednesday. The company has a quick ratio of 2.54, a current ratio of 2.74 and a debt-to-equity ratio of 0.82. The stock has a market cap of $2.47 billion, a PE ratio of 37.63 and a beta of 0.79. Supernus Pharmaceuticals has a 52-week low of $33.30 and a 52-week high of $61.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.14. The company had revenue of $99.54 million during the quarter, compared to analysts’ expectations of $101.01 million. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%. As a group, equities research analysts expect that Supernus Pharmaceuticals will post 1.93 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of SUPN. SevenBridge Financial Group LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth about $113,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth about $203,000. NumerixS Investment Technologies Inc acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter worth about $204,000. Everence Capital Management Inc. acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter worth about $205,000. Finally, Cim LLC acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter worth about $207,000. Institutional investors own 99.90% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Recommended Story: How dollar cost averaging works

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply